Detection of Suspected Paper Mill Publications in Cancer Research Using Machine Learning
January 30, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
remikiren
Class :
Renin-inhibitors
Brand Name :
N/A
Synonyms :
remikiren
Class :
Renin-inhibitors
Dosage Forms & Strengths
Hypertension (Off-label)
600
mg
Orally
once a day
8
days
In combination with hydrochlorothiazide (12.5mg or 25 mg) for 4 days
Dosage Forms & Strengths
Data not available
Refer to adult dosing
the risk of hypotensive activity of Remikiren may be increased
the hypotensive activity of acebutolol may be increased
the therapeutic activity of Remikiren may be reduced
the therapeutic effect of Remikiren may be reduced
the therapeutic effect of Remikiren may be reduced
the therapeutic effect of Remikiren may be reduced
the hypotensive activity of Remikiren may be increased
the hypotensive activity of Remikiren may be increased
the therapeutic effect of Remikiren may be reduced
the antihypertensive activity of Remikiren may be reduced
the antihypertensive activity of Remikiren may be reduced
Actions and spectrum:
Remikiren is specific for renin and does not lower arterial pressure through unrelated mechanisms, as demonstrated by a few in vivo experiments.
Frequency not defined
Syncope
Acute kidney injury
Hypotensive episodes
Renal vasodilatation
Negative sodium balance
Diarrhea
Hypokalemia
Cough
No specific black box warnings are available for this drug
Contraindication/Caution:
Contraindication:
Hypersensitivity
Angioedema
Pregnancy consideration:
USFDA pregnancy category: C
Lactation:
Data about the excretion of Remikiren into human milk is not known
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Remikiren is an angiotensin inhibitor
Pharmacodynamics:
Renin-inhibitors like Remikiren, which can be taken orally, have been shown to lower blood pressure in people with essential hypertension. There is no data available on the effects of Remikiren on the kidneys in humans. A single oral dosage of Remikiren can cause renal vasodilation in patients with essential hypertension, even though there is a marked drop in blood pressure and no effect on GFR. A more activated renin-angiotensin system results in a more pronounced systemic and renal hemodynamic response.
Pharmacokinetics:
Absorption
It is absorbed rapidly upon oral administration
Distribution
83% of the drug is known to be protein-bound
Metabolism
Data about the metabolism and excretion of Remikiren is unknown.
Administration:
The drug has to be administered orally before or after food
Patient information leaflet
Generic Name: remikiren
Why do we use Remikiren?
ACE inhibitors and angiotensin II receptor antagonists are two medications that effectively treat cardiovascular diseases by targeting the renin-angiotensin system. However, the lack of effective orally active renin inhibitors with reasonable synthesis costs and bioavailability has prevented clinical use of the system’s most obvious target, the rate-limiting enzyme renin. Remikiren is a drug belonging to the class of renin inhibitors, which is indicated in the treatment of hypertension.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
